NASDAQ: SKYASkyai Inc Stock
$1.83+0.07 (+3.98%)
Updated May 29, 2026
SKYA Price
$1.83
Fair Value Price
$0.33
Market Cap
$77.45M
52 Week Low
$1.42
52 Week High
$18.23
P/E
-1.4x
P/B
0.43x
P/S
11.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.34M
Earnings
-$370.67M
Gross Margin
92.1%
Operating Margin
-3,588.33%
Profit Margin
-3,586.2%
Debt to Equity
0.01
Operating Cash Flow
-$11M
Beta
0.76
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SKYA Overview
Sharps Technology Incorporated is a medical device company that manufactures and sells safety syringe products in the U.S. Its 'Sharps Provensa' offering is a smart safety syringe designed to eliminate potentially infectious accidental needlestick injuries Sharps Technology was incorporated in 2017 and is headquartered in Melville, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SKYA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important SKYA news, forecast changes, insider trades & much more!
SKYA News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SKYA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SKYA ($1.83) is overvalued by 459.05% relative to our estimate of its Fair Value price of $0.33 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SKYA ($1.83) is not significantly undervalued (459.05%) relative to our estimate of its Fair Value price of $0.33 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SKYA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SKYA due diligence checks available for Premium users.
Valuation
SKYA fair value
Fair Value of SKYA stock based on Discounted Cash Flow (DCF)
Price
$1.83
Fair Value
$0.33
Overvalued by
459.05%
SKYA ($1.83) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SKYA ($1.83) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SKYA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SKYA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.4x
Industry
21.32x
Market
23.22x
SKYA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.43x
Industry
2.93x
SKYA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SKYA's financial health
Profit margin
Revenue
$3.3M
Net Income
-$86.2M
Profit Margin
-2,592.2%
SKYA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SKYA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$181.0M
Liabilities
$2.2M
Debt to equity
0.01
SKYA's short-term assets ($18.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SKYA's short-term assets ($18.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SKYA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
$9.3M
Financing
-$4.7M
SKYA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SKYA vs Medical Device Stocks
Skyai Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.